UAE Oncology Drugs Market Analysis Report 2022 to 2030

UAE Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the UAE oncology drugs market will reach a value of $2.540 Bn from $1.243 Bn in 2022, growing at a CAGR of 12.6% during 2022-2030. The oncology drug market in UAE is dominated by a few large pharmaceutical companies such as Biopharma Middle East & Africa, Neopharma Pharmaceutical Plant, and Newbridge Pharmaceuticals FZ LLC. The oncology market in UAE is segmented by different therapeutic areas, into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The market is also segmented based on treatment types, such as surgery, radiation therapy, chemotherapy, and targeted therapy.

ID: IN10AEPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: UAE AUTHOR: Dr. Vishwa Modhia

Buy Now

UAE Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the UAE oncology drugs market will reach a value of $2.540 Bn from $1.243 Bn in 2022, growing at a CAGR of 12.6% during 2022-2030. Cancer is the third-leading cause of death in the United Arab Emirates (UAE); cancer care in the UAE has evolved dramatically over the last 40 years, from a single centre in Al Ain in 1981 to more than 30 cancer centres and clinics across the UAE, with at least four comprehensive cancer centers in the UAE nowadays. The UAE is determined to reduce cancer mortality by nearly 18% by 2025. Reducing the number of deaths due to cancer is one of the key performance indicators of the UAE’s national agenda as a “Pillar of World-Class Healthcare”

With the increasing cost of cancer drugs worldwide, biosimilars have been widely utilized to somewhat control the increasing cost of cancer drugs. Many biosimilars are approved in the UAE; their utilization varies between physicians and cancer centers.

Market Dynamics

Market Growth Drivers Analysis

In the UAE, it is easy to find cancer medications, including the most recent ones that have been approved. Many drugs are getting approved thanks to the UAE's quick approval process, shortly after receiving FDA approval.

Biosimilars have been widely used to partially control the rising cost of cancer medications due to the cost of cancer medications increasing across the globe. The use of biosimilars varies between doctors and cancer centers in the UAE, where many of them have been approved. For medical treatment, patients from Iraq and Africa particularly prefer the UAE. The WHO has ranked the UAE's healthcare system as the 27th best in the world.

Market Restraints

Despite the significant advancements in medicine, quality control for cancer across the UAE is still lacking, and cancer treatment varies greatly between cancer centers. Patients are still difficult to recruit for clinical trials due to a lack of knowledge, inadequate research infrastructure, and a small population.

The UAE lacks a national screening program, and early cancer detection and screening are still developing in the country. Cost is one of the obstacles to medical tourism for cancer treatment, as the cost of care tends to be higher than in other countries.

Competitive Landscape

Key Players

Biopharma Middle East & Africa (ARE)
Neopharma Pharmaceutical Plant (ARE)
Julphar Gulf Pharmaceutical Industries Manufacturers (ARE)
Newbridge Pharmaceuticals FZ LLC (ARE)
Hoffmann-La Roche Ltd
Novartis AG
Gilead Sciences Inc
Bayer AG

Notable Recent Deals

January 2023: A new exclusive licensing agreement for the anti-cancer medication Vegzelma (CT-P16, bevacizumab) has been signed by the multinational company Hikma Pharmaceuticals and the global biopharmaceutical company Celltrion Healthcare Co. According to the terms of the agreement, Celltrion Healthcare will be in charge of the development, production, and supply of Vegzelma, and Hikma will be in charge of the product's commercialization across all of its MENA markets, improving access to a critically important oncology product.

February 2022: To commemorate World Cancer Day, Pfizer has extended its collaborations with the cancer patient organizations Friends of Cancer Patients (FOCP) and Emirates Oncology Society, both of which are based in the UAE. The drug company has reaffirmed its dedication to improving oncology care, promoting early detection, and assisting with cancer treatment in the UAE.

Regulations and Reimbursement

The Emirates Oncology Society (EOS) is the official organization representing oncology healthcare providers in the UAE. It operates under the Emirates Medical Association (EMA) umbrella. The Dubai Health Authority (DHA) has defined a minimum benefits package for expatriates, the coverage level of their mandatory basic health insurance is often insufficient to fund cancer treatments.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.